The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|November 15, 2021
Rheumatoid Arthritis Quiz: RA Treatment
Author(s)Lana Pine
Rheumatoid arthritis is a complex condition. How much do you know about RA treatment?
Advertisement
Considering a patient’s mental health is an important facet of treatment.
Is the following statement true or false?
The prevalence of depression among patients with rheumatoid arthritis is likely to decrease within the first 12 months following diagnosis and treatment.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement